Welcome to our dedicated page for Nuwellis news (Ticker: NUWE), a resource for investors and traders seeking the latest updates and insights on Nuwellis stock.
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology and medical device company centered on precision fluid management for patients with cardio-renal conditions and fluid overload. News about Nuwellis frequently highlights clinical data, regulatory milestones, pediatric innovation, and business updates related to its Aquadex SmartFlow® ultrafiltration system and its Vivian™ pediatric continuous renal replacement therapy (CRRT) platform in development.
Readers of this NUWE news page can follow company announcements on topics such as new patents for extracorporeal safety technologies, NIH grant-supported development of the Vivian pediatric system, and multi-center registries like ULTRA-Peds that examine real-world Aquadex use in critically ill children. Nuwellis also issues news about clinical experiences at hospitals, including studies presented at nephrology conferences that explore Aquadex applications in acute kidney injury, post-cardiac-surgery fluid overload, and complex critical-care cases.
In addition to clinical and technology updates, Nuwellis regularly reports quarterly financial results, at-the-market equity offering arrangements, and other material events through press releases and SEC-referenced communications. These updates provide insight into revenue trends, product launches such as new catheter sizes or circuits, and strategic steps like focusing on U.S. market growth.
Investors, clinicians, and researchers can use this news feed to track how Nuwellis is advancing its Aquadex platform, expanding into pediatric and hospital-based outpatient settings, and progressing the Vivian pediatric CRRT system. Returning to this page allows users to monitor ongoing developments in the company’s cardio-renal strategy, intellectual property portfolio, and regulatory and clinical milestones associated with NUWE.
Nuwellis (Nasdaq: NUWE) will participate in the AATS 106th Annual Meeting May 2–5 in Chicago and attend the ERAS Cardiac Spring Retreat. The company will showcase its Aquadex SmartFlow ultrafiltration system for fluid removal at Booth 530 and engage with cardiac surgery thought leaders.
Nuwellis (NASDAQ: NUWE) released a software update for the Aquadex SmartFlow ultrafiltration platform on April 21, 2026. The update reduces ultrafiltration step size from 10 mL/hr to 5 mL/hr, adds a refined blood flow algorithm to reduce nuisance alarms, improves clotting visibility, and expands hourly therapy logs. The update targets improved usability and more precise fluid management for pediatric patients and is available to existing customers at no cost via standard deployment with field support.
Nuwellis (NASDAQ: NUWE) announced the return of three former employees on April 16, 2026: Liby Cielo (Principal Account Manager), Meredith Stein (Senior Clinical Education Specialist), and Scott Campbell (Area Vice President, Sales). The hires aim to accelerate commercial adoption and clinical support for Aquadex therapy across hospital and outpatient settings.
The company emphasized rebuilding commercial and clinical capacity, regional growth in South Texas and the western U.S., expanded clinician education, and support for adult and pediatric fluid‑overload patients following recent reimbursement progress.
Nuwellis (Nasdaq: NUWE) has retained CORE IR for public relations, shareholder communications, and social media management, effective April 9, 2026. CORE IR will drive market awareness, convey Nuwellis' solutions and development plans, and manage digital communications to investors, partners, and key stakeholders.
The engagement aims to support Nuwellis' growth strategy and expand outreach across medical device and diagnostics markets through integrated multi-channel communications.
Nuwellis (Nasdaq: NUWE) announced creation of a dedicated South Texas commercial territory on April 7, 2026 to strengthen hospital engagement and expand access to Aquadex therapy in a region with large hospital systems and leading cardiac and critical care programs.
The focused territory is intended to provide more direct clinical support to physicians and care teams evaluating advanced fluid management strategies, reinforcing Nuwellis’ commercial infrastructure and partnerships with hospitals treating complex cardiorenal patients.
Nuwellis (Nasdaq: NUWE) reports its pediatric category became the largest and fastest-growing segment in 2025, representing approximately 50% of total U.S. revenue. The pediatric footprint expanded to 47 centers, including six of the top 10 children’s hospitals, supporting repeat utilization and institutional adoption.
The company notes Aquadex is FDA-cleared for patients ≥20 kg, and management expects pediatric growth to remain a core strategic driver as clinical evidence and market access expand.
Nuwellis (Nasdaq: NUWE) completed its acquisition of Rendiatech on March 17, 2026, adding automated continuous kidney function monitoring to its fluid management platform.
The deal brings real-time renal monitoring technology to complement the Aquadex SmartFlow System and aims to support earlier AKI detection and future renal analytics development.
Nuwellis (Nasdaq: NUWE) reported Q4 2025 revenue of $2.4 million, up 4% year-over-year and 9% sequentially, driven by a 208% increase in U.S. console sales and higher ASPs. Q4 gross margin rose to 68.2% from 58.4% a year earlier.
Full year 2025 revenue was $8.3 million, down 5% versus 2024. Operating loss for Q4 was about $2.4 million; full-year net loss attributable to common shareholders was $17.5 million, which included a $6.4 million non-cash warrant valuation expense. The company closed a $5.0 million private placement in January 2026, appointed a new CFO, and executed a definitive agreement to acquire Rendiatech.
Nuwellis (Nasdaq: NUWE) appointed Dr. Stuart L. Goldstein as Director of Clinical Strategy on March 5, 2026, strengthening clinical leadership for its cardiorenal and pediatric focus.
Dr. Goldstein, a noted pediatric nephrology and critical care expert, will advise on product development, evidence generation, pediatric innovation, and educational initiatives to advance precision fluid management and AKI care.
Nuwellis (Nasdaq: NUWE) appointed David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. The hires add public company leadership, medical device commercialization experience and capital-markets expertise to support execution of the company’s strategic priorities.
Martin Emerson brings experience leading device companies through scaling and exits, including an acquisition by BTG, and prior leadership at an organization with over $500 million in annual revenue. David McDonald returns to the board with 25+ years in healthcare capital markets and a track record of raising nearly $200 million.